Mice With Cardiac Overexpression of Peroxisome Proliferator–Activated Receptor (cid:1) Have Impaired Repolarization and Spontaneous Fatal Ventricular Arrhythmias

Background —Diabetes mellitus and obesity, which confer an increased risk of sudden cardiac death, are associated with cardiomyocyte lipid accumulation and altered cardiac electric properties, manifested by prolongation of the QRS duration and QT interval. It is difficult to distinguish the contribution of cardiomyocyte lipid accumulation from the contribution of global metabolic defects to the increased incidence of sudden death and electric abnormalities. Methods and Results —In order to study the effects of metabolic abnormalities on arrhythmias without the complex systemic effects of diabetes mellitus and obesity, we studied transgenic mice with cardiac-specific overexpression of peroxisome proliferator–activated receptor (cid:1) 1 (PPAR (cid:1) 1) via the cardiac (cid:2) -myosin heavy-chain promoter. The PPAR (cid:1) transgenic mice develop abnormal accumulation of intracellular lipids and die as young adults before any significant reduction in systolic function. Using implantable ECG telemeters, we found that these mice have prolongation of the QRS and QT intervals and spontaneous ventricular arrhythmias, including polymorphic ventricular tachycardia and ventricular fibrillation. Isolated cardiomyocytes demonstrated prolonged action potential duration caused by reduced expression and function of the potassium channels responsible for repolarization. Short-term exposure to pioglitazone, a PPAR (cid:1) agonist, had no effect on mortality or rhythm in WT mice but further exacerbated the arrhythmic phenotype and increased the mortality in the PPAR (cid:1) transgenic mice. Conclusions —Our findings support an important link between PPAR (cid:1) activation, cardiomyocyte lipid accumulation, ion channel remodeling, and increased cardiac mortality. ( Circulation . 2011;124:2812-2821.) test with equal variances was used for comparisons of larger groups. A 2-tailed value of P (cid:3) 0.05 was considered statistically significant, except for ECG intervals and premature ventricular complexes (PVCs) burden where the Bonferroni correction was used for multiple comparisons. Linear regression analysis was performed using GraphPad Software. and ventricular fibrillation. Isolated cardiomyocytes demonstrated prolonged action potential duration caused by reduced potassium currents, which are responsible for repolarization. Short-term exposure to pioglitazone, a PPAR (cid:1) agonist, had no effect on mortality or rhythm in wild-type mice but further exacerbated the arrhythmic phenotype and increased mortality in the PPAR (cid:1) mice. Our findings support an important link between PPAR (cid:1) activation, cardiomyocyte lipid accumulation, ion channel remodeling, and increased cardiac mortality. This mouse model may help identify the molecular mechanisms leading to sudden death in diabetic and/or obese patients. with 0.3% H 2 O 2 to block endogenous peroxidase. Sections were incubated with rabbit polyclonal antibodies against Cx43 (1:200 dilution, Invitrogen Corp.) or non-immune rabbit polyclonal IgG at the same concentration, at 4˚C overnight. For DAB staining, after exposure to anti-rabbit swine antibody conjugated to biotin (1:500, DakoCytomation Denmark A/S, Glostrup, Denmark) for 1 hr in room temperature, the sections were treated with peroxidase-labeled ABC (VECTASATIN ABC Kit, Vector Laboratories, Inc., Burlingame, CA) and developed with DAB solution (ImmPACT DAB Peroxidase Substrate, Vector Laboratories, Inc.). After the reaction, the sections were counterstained with hematoxylin and observed by a light microscope. For immunofluorescent staining, after reaction with anti-rabbit donkey antibody conjugated to Alexa Fluor 488 (1:500, Invitrogen Corp.), the sections were counterstained with DAPI and observed by a fluorescent microscope. Tissues from two mice in each group (PPAR γ overexpression and WT littermates) were used. Slides were photographed with a digital camera. Signal intensity was quantified using ImageJ software (NIH).

[1]  J. Pankow,et al.  Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study , 2010, Acta Diabetologica.

[2]  Rita Ouellet-Hellstrom,et al.  Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. , 2010, JAMA.

[3]  Nan-Hung Pan,et al.  Oxidative stress and inflammation modulate peroxisome proliferator‐activated receptors with regional discrepancy in diabetic heart , 2010, European journal of clinical investigation.

[4]  J. Witteman,et al.  Serum glucose and insulin are associated with QTc and RR intervals in nondiabetic elderly. , 2010, European journal of endocrinology.

[5]  M. Kawai,et al.  Heart rate-corrected QT interval in resting ECG predicts the risk for development of type-2 diabetes mellitus , 2010, European Journal of Epidemiology.

[6]  Yibo Wang,et al.  Patients with Metabolic Syndrome Have Prolonged Corrected QT Interval (QTc) , 2009, Clinical cardiology.

[7]  G. Paolisso,et al.  Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome[S] , 2009, Journal of Lipid Research.

[8]  B. Baird,et al.  Effect of Pioglitazone on Survival and Renal Function in a Mouse Model of Polycystic Kidney Disease , 2009, American Journal of Nephrology.

[9]  S. Marx,et al.  Protein kinase C isoforms differentially phosphorylate Ca(v)1.2 alpha(1c). , 2009, Biochemistry.

[10]  W. Krek,et al.  Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. , 2009, Cell metabolism.

[11]  J. Stypmann,et al.  Echocardiographic assessment of global left ventricular function in mice , 2009, Laboratory animals.

[12]  C. R. Wilson,et al.  Adaptation and Maladaptation of the Heart in Obesity , 2008, Hypertension.

[13]  J. Nerbonne,et al.  PPARalpha-mediated remodeling of repolarizing voltage-gated K+ (Kv) channels in a mouse model of metabolic cardiomyopathy. , 2008, Journal of molecular and cellular cardiology.

[14]  G. Mazzaglia,et al.  Out of hospital sudden cardiac death in Italy: a population-based case–control study , 2008, Journal of cardiovascular medicine.

[15]  Gregory S. Harris,et al.  PPAR-γ expression in animals subjected to volume overload and chronic Urotensin II administration , 2008, Peptides.

[16]  G. Fishman,et al.  Electrical remodeling contributes to complex tachyarrhythmias in connexin43‐deficient mouse hearts , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  Michael D. Schneider,et al.  Abnormal Conduction and Morphology in the Atrioventricular Node of Mice With Atrioventricular Canal–Targeted Deletion of Alk3/Bmpr1a Receptor , 2007, Circulation.

[18]  C. Glass,et al.  Anti-inflammatory and antidiabetic roles of PPARgamma. , 2007, Novartis Foundation symposium.

[19]  L. Orci,et al.  Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. , 2007, Circulation research.

[20]  E. Abel,et al.  Diabetic cardiomyopathy revisited. , 2007, Circulation.

[21]  T. O’Connell,et al.  Isolation and culture of adult mouse cardiac myocytes. , 2007, Methods in molecular biology.

[22]  A. Moss,et al.  Obesity As a Risk Factor for Sustained Ventricular Tachyarrhythmias in MADIT II Patients , 2007, Journal of cardiovascular electrophysiology.

[23]  Guy Salama,et al.  Mouse models of long QT syndrome , 2007, The Journal of physiology.

[24]  M. Russell,et al.  Cardiomyocyte-Specific Knockout and Agonist of Peroxisome Proliferator–Activated Receptor-γ Both Induce Cardiac Hypertrophy in Mice , 2005, Circulation research.

[25]  S. Homma,et al.  Peroxisome Proliferator-Activated Receptor Agonists Modulate Heart Function in Transgenic Mice with Lipotoxic Cardiomyopathy , 2005, Journal of Pharmacology and Experimental Therapeutics.

[26]  Xianlin Han,et al.  Transgenic Expression of Fatty Acid Transport Protein 1 in the Heart Causes Lipotoxic Cardiomyopathy , 2005, Circulation research.

[27]  G. Fishman,et al.  Modulation of Cardiac Gap Junction Expression and Arrhythmic Susceptibility , 2004, Circulation research.

[28]  G. Breithardt,et al.  Phytanic Acid Accumulation Is Associated with Conduction Delay and Sudden Cardiac Death in Sterol Carrier Protein‐2/Sterol Carrier Protein‐x Deficient Mice , 2004, Journal of cardiovascular electrophysiology.

[29]  G. Noon,et al.  Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  J. Nerbonne,et al.  Heterogeneous expression of repolarizing, voltage‐gated K+ currents in adult mouse ventricles , 2004, The Journal of physiology.

[31]  Tobias Opthof,et al.  Slow Conduction and Enhanced Anisotropy Increase the Propensity for Ventricular Tachyarrhythmias in Adult Mice With Induced Deletion of Connexin43 , 2004, Circulation.

[32]  JoAnn E. Manson,et al.  Prospective Study of Sudden Cardiac Death Among Women in the United States , 2003, Circulation.

[33]  M R Franz,et al.  Monophasic Action Potential Recordings from Intact Mouse Heart: Validation, Regional Heterogeneity, and Relation to Refractoriness , 2001, Journal of cardiovascular electrophysiology.

[34]  V. Shusterman,et al.  Targeted Replacement of Kv1.5 in the Mouse Leads to Loss of the 4-Aminopyridine-Sensitive Component of IK,slow and Resistance to Drug-Induced QT Prolongation , 2001, Circulation research.

[35]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[36]  Michael D. Schneider,et al.  Conduction Slowing and Sudden Arrhythmic Death in Mice With Cardiac-Restricted Inactivation of Connexin43 , 2001, Circulation research.

[37]  N. Weissman,et al.  Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin , 2000, The Journal of physiology.

[38]  X. Jouven,et al.  Diabetes as a risk factor for sudden death , 1999, The Lancet.

[39]  J. Nerbonne,et al.  Molecular basis of transient outward K+ current diversity in mouse ventricular myocytes , 1999, The Journal of physiology.

[40]  J. Nerbonne,et al.  Attenuation of the slow component of delayed rectification, action potential prolongation, and triggered activity in mice expressing a dominant-negative Kv2 alpha subunit. , 1999, Circulation research.

[41]  M Delmar,et al.  Characterization of Conduction in the Ventricles of Normal and Heterozygous Cx43 Knockout Mice Using Optical Mapping , 1999, Journal of cardiovascular electrophysiology.

[42]  Weinong Guo,et al.  Four Kinetically Distinct Depolarization-activated K+ Currents in Adult Mouse Ventricular Myocytes , 1999, The Journal of general physiology.

[43]  P Ducimetière,et al.  Predicting sudden death in the population: the Paris Prospective Study I. , 1999, Circulation.

[44]  G. Paolisso,et al.  Association of fasting plasma free fatty acid concentration and frequency of ventricular premature complexes in nonischemic non-insulin-dependent diabetic patients. , 1997, The American journal of cardiology.

[45]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[46]  C. Chi,et al.  PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and motility of HepG2 cells. , 2009, Anticancer research.

[47]  J. Nerbonne,et al.  Kv4.3 is not required for the generation of functional Ito,f channels in adult mouse ventricles. , 2008, Journal of molecular and cellular cardiology.

[48]  S. Homma,et al.  Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. , 2007, The Journal of clinical investigation.

[49]  D. Gómez-Garre,et al.  Activation of peroxisome proliferator-activated receptor-alpha and -gamma in auricular tissue from heart failure patients. , 2006, European journal of heart failure.

[50]  A. Chawla,et al.  Role of PPARgamma in macrophage biology and atherosclerosis. , 2004, Trends in endocrinology and metabolism: TEM.

[51]  W. Koenig,et al.  Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[52]  Xianlin Han,et al.  The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. , 2002, The Journal of clinical investigation.